Peripheral Androgen Blockade Feasible for PSA Relapse

Share this article:

Peripheral androgen blockade with a combination of finasteride and flutamide is feasible for prostate cancer patients who experience biochemical failure after definitive local therapy, researchers reported online ahead of print in Cancer.

In a study, 99 such patients received finasteride 5 mg orally per day and flutamide 250 mg orally three times a day. Investigators observed an 80% or greater decline in PSA in 96 patients (96%). Five-year overall survival was 87%. Toxicities were mild.

The researchers, led by J. Paul Monk, MD, of The Ohio State University School of Medicine in Columbus, noted that “because testosterone levels are not suppressed, this approach may be associated with less morbidity than conventional gonadal androgen suppression.”

Share this article:
You must be a registered member of RUN to post a comment.
close

Next Article in Prostate Cancer

More in Prostate Cancer

Prostate Brachytherapy On the Decline

Use of this treatment for localized prostate cancer has been decreasing since 2002, perhaps due to increasing use of radical prostatectomy.

Adding ADT to Radiotherapy Improves Prostate Cancer Outcomes

Adding ADT to Radiotherapy Improves Prostate Cancer Outcomes

The combined treatment was associated with a reduced risk of biochemical and clinical progression compared with radiotherapy alone.

Osteoporosis May Be Present Before Prostate Cancer ADT

Osteoporosis May Be Present Before Prostate Cancer ADT

Danish study reveals a 10% prevalence of osteoporosis among men due to start androgen-deprivation therapy.